C. Lang

发表

Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study

S. Yusuf, Li-sheng Liu, Arya M. Sharma, 2005, The Lancet.

Cardiotoxicity and Chemotherapy—The Role of Precision Medicine

C. Lang, R. Petty, T. Viswanathan, 2021, Diseases.

Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (the MET-REMODEL study): rationale and design of the MET-REMODEL study.

C. Lang, M. Mohan, S. McSwiggan, 2015, Cardiovascular therapeutics.

Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study

S. Yusuf, A. Dans, H. Gerstein, 2010, Diabetologia.

University of Dundee Effect of the 2017 European Guidelines on Reclassification of Severe Aortic Stenosis and Its Influence on Management Decisions for Initially Asymptomatic Aortic Stenosis

M. Dweck, C. Berry, J. Greenwood, 2020 .

Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART Study.

S. Yusuf, P. Pais, G. Karthikeyan, 2009, Journal of the American College of Cardiology.

Interactions between atrial natriuretic factor and the autonomic nervous system

A. Struthers, C. Lang, 1991, Clinical Autonomic Research.

Mind your language: conveying the results of clinical trials of cardiovascular therapies.

H. Krum, C. Lang, 2013, Cardiovascular therapeutics.

DIAGNOSIS OF TYPE 1a AND TYPE 1c GLYCOGEN STORAGE DISEASES IN ADULTS

R. Jung, C. Lang, W. Bennet, 1987, The Lancet.

Metabolic antianginal agent ranolazine offers good symptom relief in a patient with inoperable severe aortic stenosis.

C. Lang, Pandula Athauda‐arachchi, 2012, Cardiovascular therapeutics.

Ranolazine in refractory and chronic stable angina

C. Lang, A. Mirza, James D Noyes, 2020 .

Isolated large vessel pulmonary vasculitis as a cause of chronic obstruction of the pulmonary arteries

D. Rassl, C. Lang, D. Gopalan, 2011, Pulmonary circulation.

Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES.

R. McKelvie, E. Lonn, C. Lang, 2007, Journal of the American College of Cardiology.

Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study.

S. Padmanabhan, I. Menown, C. Lang, 2013, International journal of cardiology.

The differential effects of circulating norepinephrine and neuronally released norepinephrine on sodium excretion in humans

C. Lang, A. Struthers, C. Lang, 1993, Clinical pharmacology and therapeutics.

Resting Heart Rate and Outcomes in Patients with Cardiovascular Disease: Where Do We Currently Stand?

S. Davies, S. Padmanabhan, I. Menown, 2013, Cardiovascular therapeutics.

Management of Noncardiac Comorbidities in Chronic Heart Failure.

D. Mancini, C. Lang, Farhad R. Chowdhury, 2015, Cardiovascular therapeutics.

Pharmacogenetics testing: implications for cardiovascular therapeutics with clopidogrel and warfarin.

A. Doney, C. Palmer, C. Lang, 2010, Cardiovascular therapeutics.

ATTITUDES OF PHYSICIANS IN THE TREATMENT OF CONGESTIVE HEART FAILURE IN OLDER ADULTS

M. Mcmurdo, A. Struthers, D. Darbar, 1995, Journal of the American Geriatrics Society.

The effect of intravenous saline loading on plasma levels of brain natriuretic peptide in man

C. Lang, A. Struthers, A. Choy, 1993, Journal of hypertension.

1108-109 Low hemoglobin is an independent predictor of adverse fatal and nonfatal outcomes in both reduced and preserved systolic function chronic heart failure: Findings from the candesartan in heart failure assessment of reduction in mortality and morbidity program (CHARM)

M. Pfeffer, S. Yusuf, K. Swedberg, 2004 .

The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study.

Benjamin R. Szwejkowski, A. Doney, S. Pringle, 2011, Journal of the American College of Cardiology.

Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study

P. Donnan, A. Morris, A. Doney, 2008, Pharmacogenetics and genomics.

Decreased intestinal CYP3A in celiac disease: Reversal after successful gluten‐free diet: A potential source of interindividual variability in first‐pass drug metabolism

C. Lang, F. Guengerich, C. Lang, 1996, Clinical pharmacology and therapeutics.

Comparison of exercise testing and CMR measured myocardial perfusion reserve for predicting outcome in asymptomatic aortic stenosis: the PRognostic Importance of MIcrovascular Dysfunction in Aortic Stenosis (PRIMID AS) Study

B. Prendergast, N. Samani, S. Neubauer, 2017, European heart journal.

Drug management of pain caused by cancer: a study of general practitioners' treatment attitudes and practices

C. Lang, W. Macrae, P. H. Beardon, 1992 .

1 Obesity and the risk of myocardial infarction in 27 , 000 participants from 52 countries : a case-control study The Lancet

S. Yusuf, Arya M. Sharma, S. Hawken, 2005 .

Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (TZD-IMPACT) study.

C. Lang, S. Hannah, J. George, 2009, Cardiovascular therapeutics.

Enalapril blunts the antinatriuretic effect of circulating noradrenaline in man

A. Struthers, C. Lang, D. Balfour, 1993, Journal of hypertension.

Hypertension in black people: study of specific genotypes and phenotypes will provide a greater understanding of interindividual and interethnic variability in blood pressure regulation than studies based on race.

C. Lang, C. Stein, C. Lang, 2001, Pharmacogenetics.

Modulation of the Renin-Angiotensin-Aldosterone System in Heart Failure

C. Lang, A. Struthers, C. Lang, 2014, Current Atherosclerosis Reports.

Atrial and brain natriuretic peptides: a dual natriuretic peptide system potentially involved in circulatory homeostasis.

C. Lang, A. Struthers, A. Choy, 1992, Clinical science.